Prime Medicine furnishes Q3 2025 results press release (8‑K)

Prime Medicine, Inc. (PRME) furnished an 8‑K to announce it issued a press release covering financial results and business highlights for the quarter ended September 30, 2025.

Rhea-AI Filing Summary

Prime Medicine, Inc. (PRME) furnished an 8‑K to announce it issued a press release covering financial results and business highlights for the quarter ended September 30, 2025.

The disclosure was made under Item 2.02 and includes Exhibit 99.1 (Press Release dated November 7, 2025). The information is furnished and shall not be deemed filed under Section 18 of the Exchange Act, nor incorporated by reference, except as expressly stated by specific reference.

Prime Medicine’s common stock trades on The Nasdaq Global Market under the symbol PRME.

8-K Event Classification

2 items: 2.02, 9.01

2 items

Item 2.02 Results of Operations and Financial Condition Financial

Disclosure of earnings results, typically an earnings press release or preliminary financials.

Item 9.01 Financial Statements and Exhibits Exhibits

Financial statements, pro forma financial information, or exhibit attachments filed with this report.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did PRME report in its latest 8-K?

PRME furnished a press release announcing financial results and business highlights for the quarter ended September 30, 2025.

Which 8-K item applies to PRME’s disclosure?

The information was provided under Item 2.02 (Results of Operations and Financial Condition).

Where can I find the detailed results for PRME?

See Exhibit 99.1, the Press Release dated November 7, 2025, furnished with the 8‑K.

Is PRME’s press release considered filed or furnished?

It is furnished and shall not be deemed filed under Section 18 of the Exchange Act.

What period does the PRME update cover?

The update covers the quarter ended September 30, 2025.

What is PRME’s trading symbol and exchange?

PRME common stock trades on The Nasdaq Global Market under the symbol PRME.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Understanding 8-K Material Events →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 11/07/2025 - 07:27 AM EST Learn about SEC filing dates

0001894562false00018945622025-11-072025-11-07

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

___________________________________

FORM 8-K

___________________________________

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

November 7, 2025

Date of Report (Date of earliest event reported)

___________________________________

Prime Medicine, Inc.

(Exact name of registrant as specified in its charter)

___________________________________

Delaware (State or other jurisdiction of incorporation)			001-41536 (Commission File Number)			84-3097762 (I.R.S. Employer Identification No.)
60 First Street Cambridge, MA						02141
(Address of principal executive offices)						(Zip Code)
(617) 465-0013
(Registrant's telephone number, including area code)

___________________________________

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐			Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐			Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐			Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐			Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class

Trading Symbol(s)

Name of each exchange on which registered

Common stock, par value $.00001 per share

PRME

The Nasdaq Global Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule12b-2 of the Securities Exchange Act of 1934 (§250.12b-2 of this chapter).

Emerging growth company    ☒

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 2.02 Results of Operations and Financial Condition.

On November 7, 2025, Prime Medicine, Inc. (the “Company”) issued a press release announcing its financial results and business highlights for the quarter ended September 30, 2025. A copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K.

The information contained in Item 2.02 of this Current Report on Form 8-K, including Exhibit 99.1 attached hereto, is intended to be furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934 (the “Exchange Act”) or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933 or the Exchange Act, except as expressly set forth by specific reference in such a filing.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits

Exhibit Number						Description
99.1						Press Release, dated November 7, 2025, furnished herewith.
104						Cover Page Interactive Data File (embedded within the Inline XBRL document)

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Date: November 7, 2025

Prime Medicine, Inc.
By:			/s/ Allan Reine
Name:			Allan Reine
Title:			Chief Executive Officer